The expanding vaccine development pipeline, 1995-2008

被引：21

作者：

Davis, Matthew M. ^{[1
,2
,3
,5
]}

Butchart, Amy T.

Coleman, Margaret S. ^{[5
]}

Singer, Dianne C.

Wheeler, John R. C. ^{[4
]}

Pok, Angela

Freed, Gary L. ^{[4
]}

机构：

[1] Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, Div Gen Pediat, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Div Gen Internal Med, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA

[4] Univ Michigan, Dept Hlth Policy & Management, Sch Publ Hlth, Ann Arbor, MI 48109 USA

[5] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA

来源：

VACCINE | 2010年 / 28卷 / 05期

关键词：

Vaccine; Clinical trials; Industry; INVASIVE PNEUMOCOCCAL DISEASE; UNITED-STATES; VARICELLA VACCINATION; CONJUGATE VACCINE; DRUG DEVELOPMENT; DECLINE; IMPACT; COSTS;

D O I：

10.1016/j.vaccine.2009.11.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Successful launches of recently licensed vaccines contrast with pharmaceutical industry concerns about unfavorable market conditions, making the status and future of vaccine development uncertain. We assessed trends in private-sector vaccine research and development for the period 1995-2008, using a global pharmaceutical database to identify prophylactic vaccines in preclinical, Phase I, Phase II, or Phase III stages of development. We counted companies that research and/or manufacture vaccines ("vaccine originators") and their vaccine products in each year. The global number of vaccine originators doubled (to 136), as did the number of prophylactic vaccine products in development (to 354); the majority of this growth was in preclinical and early phase clinical research. Because rapid growth in earlier research phases has not yet led to growth in Phase III, it is not yet clear whether recent industry expansion will translate to an increase in the number of available vaccines in the near future. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1353 / 1356

页数：4

共 17 条

[11] Why are pharmaceutical companies gradually abandoning vaccines? [J].

Offit, PA .

HEALTH AFFAIRS, 2005, 24 (03) :622-630

[12] Why certain vaccines have been delayed or not developed at all [J].

Plotkin, SA .

HEALTH AFFAIRS, 2005, 24 (03) :631-634

[13] Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine [J].

Poehling, KA ;

Talbot, TR ;

Griffin, MR ;

Craig, AS ;

Whitney, CG ;

Zell, E ;

Lexau, CA ;

Thomas, AR ;

Harrison, LH ;

Reingold, AL ;

Hadler, JL ;

Farley, MM ;

Anderson, BJ ;

Schaffner, W .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1668-1674

[14] BIOPHARMACEUTICAL R-AND-D SUCCESS RATES AND DEVELOPMENT TIMES [J].

STRUCK, MM .

BIO-TECHNOLOGY, 1994, 12 (07) :674-677

[15] Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine [J].

Whitney, CG ;

Farley, MM ;

Hadler, J ;

Harrison, LH ;

Bennett, NM ;

Lynfield, R ;

Reingold, A ;

Cieslak, PR ;

Pilishvili, T ;

Jackson, D ;

Facklam, RR ;

Jorgensen, JH ;

Schuchat, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1737-1746

[16] Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001 [J].

Zhou, FJ ;

Santoli, J ;

Messonnier, ML ;

Yusuf, HR ;

Shefer, A ;

Chu, SY ;

Rodewald, L ;

Harpaz, R .

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2005, 159 (12) :1136-1144

[17] Impact of varicella vaccination on health care utilization [J].

Zhou, FJ ;

Harpaz, R ;

Jumaan, AO ;

Winston, CA ;

Shefer, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (07) :797-802

← 1 2 →